Heron Financial Group LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 10.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,980 shares of the company’s stock after purchasing an additional 946 shares during the period. Johnson & Johnson comprises 0.9% of Heron Financial Group LLC’s holdings, making the stock its 27th biggest holding. Heron Financial Group LLC’s holdings in Johnson & Johnson were worth $1,547,000 at the end of the most recent quarter.
Several other hedge funds also recently added to or reduced their stakes in the company. Moneta Group Investment Advisors LLC grew its stake in Johnson & Johnson by 90,144.4% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after acquiring an additional 54,326,454 shares in the last quarter. Norges Bank bought a new position in Johnson & Johnson in the 4th quarter worth about $4,609,399,000. Morgan Stanley grew its stake in Johnson & Johnson by 12.0% in the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after acquiring an additional 4,521,062 shares in the last quarter. Nordwand Advisors LLC bought a new position in Johnson & Johnson in the 4th quarter worth about $785,273,000. Finally, Price T Rowe Associates Inc. MD grew its stake in Johnson & Johnson by 15.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock worth $5,171,919,000 after acquiring an additional 3,849,148 shares in the last quarter. 67.57% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of equities analysts have commented on the stock. Morgan Stanley upped their target price on shares of Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 19th. Raymond James lowered their price target on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research report on Wednesday, April 19th. UBS Group began coverage on shares of Johnson & Johnson in a research report on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price target for the company. StockNews.com began coverage on shares of Johnson & Johnson in a research report on Thursday, May 18th. They issued a “strong-buy” rating for the company. Finally, Atlantic Securities lowered their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research report on Wednesday, April 19th. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $171.57.
Insiders Place Their Bets
Johnson & Johnson Trading Down 0.7 %
NYSE:JNJ opened at $161.60 on Friday. The firm has a 50 day moving average of $160.72 and a 200 day moving average of $162.73. The stock has a market capitalization of $419.95 billion, a price-to-earnings ratio of 33.81, a PEG ratio of 2.79 and a beta of 0.55. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $181.04. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.49.
Johnson & Johnson (NYSE:JNJ – Free Report) last posted its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. The business had revenue of $24.75 billion during the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The business’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the company posted $2.67 earnings per share. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The business also recently declared a quarterly dividend, which was paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd were issued a $1.19 dividend. The ex-dividend date of this dividend was Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.95%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio (DPR) is currently 99.58%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- Order From U.S. Army Fuels Surge In Enovix Stock
- The Bottom Is In For Mullen Automotive
- Could Meta Be Risking Another Sell Off With Its New “Threads”?
- 2 Must-Have Specialized ETFs for the Long-Term Investor
- Inspire Medical Up 15% After Breakout, Analysts Say It’s A Buy
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
